Drugs Information:
Ertugliflozin
Basic Information
|
||
ID | DDInter669 | |
Drug Type | small molecule | |
Molecular Formula | C22H25ClO7 | |
Molecular Weight | 436.890 | |
CAS Number | 1210344-57-2 | |
Description | Ertugliflozin belongs to the class of potent and selective inhibitors of the sodium-dependent glucose cotransporters (SGLT), more specifically the type 2 which is responsible for about 90% of the glucose reabsorption from glomerulus.[A31581] This drug was developed under the collaboration of Merck and Pfizer. It was FDA approved as monotherapy and in combination with sitagliptin or metformin hydrochloride on December 22, 2017.[L1132] | |
ATC Classification | A10BD23 A10BK04 A10BD24 | |
IUPAC Name | (1S,2S,3S,4R,5S)-5-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol | |
InChI | MCIACXAZCBVDEE-CUUWFGFTSA-N | |
Canonical SMILES | CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1 | |
Useful Links | DrugBank PubChem Substance ChemSpider BindingDB Wikipedia ChEMBL ZINC |
Interactions with
Ertugliflozin
Filter:
Severity level | ID | Name | Mechanism | Detail |
---|
Interactions with diseases
Filter:
Severity level | Disease name | Text | References |
---|
Interactions with foods
Filter:
Severity level | Food name | Description | Management | Mechanism | References |
---|
Interactions with compound preparation
Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
---|